These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

150 related items for PubMed ID: 8390605

  • 1. alpha-Bungarotoxin sensitization in experimental autoimmune myasthenia gravis.
    Kennel PF, Poindron P, Warter JM, Fonteneau P.
    Muscle Nerve; 1993 May; 16(5):461-5. PubMed ID: 8390605
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Mice with IFN-gamma receptor deficiency are less susceptible to experimental autoimmune myasthenia gravis.
    Zhang GX, Xiao BG, Bai XF, van der Meide PH, Orn A, Link H.
    J Immunol; 1999 Apr 01; 162(7):3775-81. PubMed ID: 10201893
    [Abstract] [Full Text] [Related]

  • 9. Antigenic modulation of junctional acetylcholine receptor is not sufficient to account for the development of myasthenia gravis in receptor immunized mice.
    Berman PW, Heinemann SF.
    J Immunol; 1984 Feb 01; 132(2):711-7. PubMed ID: 6690616
    [Abstract] [Full Text] [Related]

  • 10. beta-Bungarotoxin binding protein is immunogenic but lacks myasthenogenicity in rats.
    Qiao J, Wang ZY, Link H.
    J Neurol Sci; 1994 Feb 01; 121(2):190-3. PubMed ID: 8158214
    [Abstract] [Full Text] [Related]

  • 11. Pathological mechanisms in experimental autoimmune myasthenia gravis. I. Immunogenicity of syngeneic muscle acetylcholine receptor and quantitative extraction of receptor and antibody-receptor complexes from muscles of rats with experimental automimmune myasthenia gravis.
    Lindstrom JM, Einarson BL, Lennon VA, Seybold ME.
    J Exp Med; 1976 Sep 01; 144(3):726-38. PubMed ID: 182896
    [Abstract] [Full Text] [Related]

  • 12. Pathogenesis of hyperacute experimental autoimmune myasthenia gravis. Acetylcholine receptor/cholinergic site/receptor function/autoimmunity.
    Mihovilovic M, Donnelly-Roberts D, Richman DP, Martinez-Carrion M.
    J Immunol; 1994 Jun 15; 152(12):5997-6002. PubMed ID: 8207224
    [Abstract] [Full Text] [Related]

  • 13. Lewis rats given antibodies against denatured acetylcholine receptor become resistant to induction of experimental autoimmune myasthenia gravis.
    Krolick KA, Yeh TM, Edlund SA.
    Cell Immunol; 1996 Aug 25; 172(1):10-20. PubMed ID: 8806801
    [Abstract] [Full Text] [Related]

  • 14. Immunological studies of acetylcholine receptors.
    Lindstrom J.
    J Supramol Struct; 1976 Aug 25; 4(3):389-403. PubMed ID: 817087
    [Abstract] [Full Text] [Related]

  • 15. Animal models of myasthenia gravis.
    Christadoss P, Poussin M, Deng C.
    Clin Immunol; 2000 Feb 25; 94(2):75-87. PubMed ID: 10637092
    [Abstract] [Full Text] [Related]

  • 16. Passive transfer of seronegative myasthenia gravis to mice.
    Burges J, Vincent A, Molenaar PC, Newsom-Davis J, Peers C, Wray D.
    Muscle Nerve; 1994 Dec 25; 17(12):1393-400. PubMed ID: 7969240
    [Abstract] [Full Text] [Related]

  • 17. IFN-alpha treatment suppresses the development of experimental autoimmune myasthenia gravis.
    Shenoy M, Baron S, Wu B, Goluszko E, Christadoss P.
    J Immunol; 1995 Jun 01; 154(11):6203-8. PubMed ID: 7751658
    [Abstract] [Full Text] [Related]

  • 18. Response to gallamine: an indicator of diminished neuromuscular function in experimental autoimmune myasthenia gravis.
    Hinman CL, Dambach GE, Hudson RA, Rauch HC.
    J Neurosci Res; 1985 Jun 01; 14(2):271-8. PubMed ID: 4046075
    [Abstract] [Full Text] [Related]

  • 19. Experimental autoimmune myasthenia gravis in B10.BV8S2 transgenic mice: preferential usage of TCRAV1 gene by lymphocytes responding to acetylcholine receptor.
    Kaul R, Wu B, Goluszko E, Deng C, Dedhia V, Nabozny GH, David CS, Rimm IJ, Shenoy M, Haqqi TM, Christadoss P.
    J Immunol; 1997 Jun 15; 158(12):6006-12. PubMed ID: 9190955
    [Abstract] [Full Text] [Related]

  • 20. The Th2 cytokine IL-4 is not required for the progression of antibody-dependent autoimmune myasthenia gravis.
    Balasa B, Deng C, Lee J, Christadoss P, Sarvetnick N.
    J Immunol; 1998 Sep 15; 161(6):2856-62. PubMed ID: 9743346
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 8.